Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema (EBEV)

Hospital Clinic of Barcelona

Status and phase

Terminated

Phase 3

Conditions

Uveitis

Treatments

Drug: bevacizumab

Drug: triamcinolone acetonide

Study type

Interventional

Funder types

Other

Identifiers

NCT01095809

EBEV

Details and patient eligibility

About

The purpose of this study is to determine whether intravitreous bevacizumab or intravitreous triamcinolone acetonide are effective and safe in the treatment of uveitic macular oedema

Enrollment

5 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

adult patients with uveitis or retinal vasculitis with unilateral or bilateral macular oedema
with macular thickness > 250 micra using OCT
visual acuity at least 20/200
with stable treatment with oral prednisone at least during 3 months, either oral ciclosporin or other immunomodulator to treat intraocular inflammatory disease
patient that can follow study's requirements
patient who consents to participate

Exclusion criteria

presence of corneal or crystalline opacity preventing observation of fundus of eye
patients requiring ocular surgery in next 3 months
one-eyed
pregnancy and child breastfeeding
previous history of glaucoma
on treatment woth an experimental ocular drug
previous thromboembolism or receiving oral anticoagulant treatment
vitrectomy
patients with proved tractional macular pathology associated to macular oedema